Ayvakit (avapritinib) Letter of Medical Necessity
Ayvakit (avapritinib) is a precision kinase inhibitor approved for PDGFRA exon 18–mutant GIST and for advanced and indolent systemic mastocytosis. Because it is genotype-directed and high-cost, nearly every payer requires prior authorization tied to a documented mutation test or WHO-defined mastocytosis diagnosis. Most denials are paperwork gaps, not clinical disagreements.
FDA-Approved Indications
- ● unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including D842V
- ● advanced systemic mastocytosis (ASM, SM-AHN, mast cell leukemia)
- ● indolent systemic mastocytosis
Why Ayvakit Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. PDGFRA exon 18 / D842V mutation test result not submitted (GIST)
- 2. Imatinib step therapy requested despite imatinib-resistant D842V genotype
- 3. Systemic mastocytosis subtype not documented per WHO criteria (bone marrow biopsy, KIT D816V, serum tryptase)
- 4. Platelet count not on file (not recommended below 50,000/µL in advanced SM)
- 5. Indolent SM symptom burden and failure of best supportive care (antihistamines, cromolyn, etc.) not documented
- 6. Specialty pharmacy limited-distribution enrollment incomplete
What to Include in a Ayvakit Letter of Medical Necessity
For GIST, attach the molecular pathology report confirming the PDGFRA exon 18 mutation (D842V when present) and explain why imatinib step therapy is clinically inappropriate for this genotype. For systemic mastocytosis, document the WHO diagnostic criteria met (bone marrow findings, KIT D816V, serum tryptase), the SM subtype, baseline platelet count, organ damage findings (advanced SM) or symptom burden and supportive-care failures (indolent SM), and cite the relevant NCCN recommendation.
Key clinical evidence to cite:
- ✓ NAVIGATOR Phase 1 trial — high overall response rates in PDGFRA D842V-mutant GIST, a genotype resistant to imatinib and other approved TKIs
- ✓ EXPLORER and PATHFINDER trials in advanced systemic mastocytosis
- ✓ PIONEER randomized, placebo-controlled trial in indolent systemic mastocytosis — significant improvement in total symptom score and reduction in serum tryptase
- ✓ Genotype-directed therapy: only approved agent with meaningful activity against PDGFRA D842V
Relevant guidelines:
- 📖 NCCN Gastrointestinal Stromal Tumors Guidelines
- 📖 NCCN Systemic Mastocytosis Guidelines
- 📖 WHO Classification of Mastocytosis
Ayvakit Prior Authorization Criteria
Standard criteria across major US payers for Ayvakit. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Imatinib step therapy requested despite imatinib-resistant D842V genotype
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Ayvakit
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Ayvakit Prior Authorization FAQ
Why was my Ayvakit prior authorization denied?
The most common denial reasons for Ayvakit are: PDGFRA exon 18 / D842V mutation test result not submitted (GIST); Imatinib step therapy requested despite imatinib-resistant D842V genotype; Systemic mastocytosis subtype not documented per WHO criteria (bone marrow biopsy, KIT D816V, serum tryptase); Platelet count not on file (not recommended below 50,000/µL in advanced SM); Indolent SM symptom burden and failure of best supportive care (antihistamines, cromolyn, etc.) not documented; Specialty pharmacy limited-distribution enrollment incomplete.
What should a Ayvakit Letter of Medical Necessity include?
For GIST, attach the molecular pathology report confirming the PDGFRA exon 18 mutation (D842V when present) and explain why imatinib step therapy is clinically inappropriate for this genotype. For systemic mastocytosis, document the WHO diagnostic criteria met (bone marrow findings, KIT D816V, serum tryptase), the SM subtype, baseline platelet count, organ damage findings (advanced SM) or symptom burden and supportive-care failures (indolent SM), and cite the relevant NCCN recommendation.
Which payers cover Ayvakit?
Ayvakit is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.